New <i>In Vitro</i> Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations-Reference-Cited by-同舟云学术

New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations

Published:2022-11-15 Issue:11 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Wicha Sebastian G.¹,Walz Annabelle²³,Cherkaoui-Rbati Mohammed H.⁴,Bundgaard Nils⁵,Kuritz Karsten⁵,Gumpp Christin²³,Gobeau Nathalie⁴,Möhrle Jörg⁴^ORCID,Rottmann Matthias²³,Demarta-Gatsi Claudia⁴^ORCID

Affiliation:

1. Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany

2. Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland

3. University of Basel, Basel, Switzerland

4. Medicines for Malaria Venture, Geneva, Switzerland

5. IntiQuan GmbH, Basel, Switzerland

Abstract

The development and spread of drug-resistant phenotypes substantially threaten malaria control efforts. Combination therapies have the potential to minimize the risk of resistance development but require intensive preclinical studies to determine optimal combination and dosing regimens.

Funder

Bill and Melinda Gates Foundation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00556-22

Reference31 articles.

1. World Health Organization. 2021. World malaria report 2021. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021.

2. Artemisinin-based combination therapies (ACTs): Best hope for malaria treatment but inaccessible to the needy!

3. A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria